**Background:** Low-dose and long-term administration of macrolide antibiotics into patients with chronic airway inflammatory diseases could favorably modify their clinical conditions. However, the therapeutic mode of action of macrolides is not well understood. Free oxygen radicals, including nitric oxide (NO), are well recognized as the important final effector molecules in the development and the maintenance of inflammatory diseases.

**Purpose:** The influence of macrolide antibiotics on NO generation was examined in vivo.

**Methods:** Male ICR mice, 5 weeks of age, were orally administered with either roxithromycin, clarithromycin, azithromycin or josamycin once a day for 2–4 weeks. The mice were then injected intraperitoneally with 5.0 mg/kg lipopolysaccharide (LPS) and the plasma NO level was examined 6 h later.

**Results:** Although pre-treatment of mice with macrolide antibiotics for 2 weeks scarcely affected NO generation by LPS injection, the administration of macrolide antibiotics, except for josamycin, for 4 weeks significantly inhibited LPS-induced NO generation. The data in the present study also showed that pre-treatment of mice with macrolide antibiotics for 4 weeks significantly suppresses not only production of pro-inflammatory cytokines interleukin-1β, interleukin-6, and tumor necrosis factor-α, but also inducible nitric oxide synthase mRNA expressions, which are enhanced by LPS injection.

**Conclusion:** These results strongly suggest that suppressive activity of macrolide antibiotics on NO generation in response to LPS stimulation in vivo may, in part, account for the clinical efficacy of macrolides on chronic inflammatory diseases.

**Key words:** Macrolide antibiotics, Nitric oxide, Mouse, Inducible nitric oxide synthase mRNA, Pro-inflammatory cytokine, Suppression, In vivo

---

**Introduction**

Low-dose and long-term administration of macrolide antibiotics, so-called macrolide therapy, is reported to be effective in the treatment and the management of chronic inflammatory diseases, such as panbronchiolitis and chronic sinusitis. It is also observed that administration of azithromycin (AZM), a newly developed 15-membered macrolide antibiotic, could modify the clinical condition of cystic fibrosis. Although the precise mechanisms of the macrolide therapy are not well understood, there is circumstantial evidence that the therapeutic mode of macrolides is due in part to their anti-inflammatory, rather than antibacterial, effects.

It is reported that an accumulation of both neutrophils and macrophages in the airway is an important feature of the diseases, which is normalized after appropriate macrolide therapies. It is also recognized that, in response to antigenic stimulation, these inflammatory cells can secret not only inflammatory cytokines, but also free oxygen radicals such as O₂⁻ and H₂O₂. Our previous work clearly shows the suppressive activity of macrolide antibiotics on inflammatory cytokine production from inflammatory cells, including T cells, mast cells and macrophages in vitro and in vivo. However, there is little information about the influence of macrolide antibiotics on free oxygen radical generation from inflammatory cells.

Nitric oxide (NO) is recognized as one of the important regulators of many cell and tissue functions. It is also accepted that NO is produced from various types of cells and tissues in response to inflammatory stimuli. Although NO is generally believed to be a short-lived gaseous free radical, it reacts extremely rapidly with superoxide and produces the very reactive and toxic peroxinitrite, which

---

Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice

Hajime Terao¹, Kazuhiro Asano², Ken-ichi Kanai¹, Yoshiyuki Kyo³, So Watanabe¹, Tadashi Hisamitsu² and Harumi Suzaki¹. CA

¹Department of Otolaryngology and ²Department of Physiology, School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo 142-8666, Japan

CA Corresponding Author
Tel: +81 3 3784 8676
Fax: +81 3 3784 3757
E-mail: h-suzaki@mve.biglobe.ne.jp

Mediators of Inflammation, 12(4), 195–202 (August 2003)
subsequently decomposes into additional highly reactive intermediates. Clinical evidence has clearly shown that NO concentration in exhaled air is increased in patients with airway inflammations, including rhinitis, as compared with normal subjects. Recently, nitrogen derived from oxidants was found to play a role in airway diseases as one of the final effector molecules, suggesting the possibility of an important role for peroxynitrite in inflammatory airway diseases. Recent in vitro studies clearly showed that macrolide antibiotics, such as erythromycin and roxithromycin (RXM), significantly suppress NO generation from both macrophages and nasal fibroblasts in response to inflammatory stimuli. These reports may suggest that macrolide antibiotics exert an attenuating effect on chronic inflammatory diseases through suppression of NO generation. However, before drawing the conclusion that this suppressive activity of macrolide antibiotics underlies one of the therapeutic modes of action of agents on the diseases, it is necessary to examine whether macrolide antibiotics could also suppress NO generation in vivo. In the present study, therefore, we examined the influence of macrolide antibiotics on NO generation in vivo using an experimental mouse model.

Materials and methods

Mouse
Specific pathogen free ICR mice were purchased from Charles River Japan Inc. (Atsugi, Japan). After arrival at our university, they were kept in filter (0.2 μm)-barriered cages, and provided with autoclaved food and tap water ad libitum throughout the experiments to prevent un-wanted microbiological infection. The rats were all male and 5 weeks of age at the start of experiments. All animal experimental procedures were approved by the Animal Care and Use Committee of Showa University and were carried out in accordance with the guidelines of the Physiological Society of Japan.

Antibiotics
RXM was kindly donated by Aventis Pharmaceutical Co. Ltd (Tokyo, Japan) as a water-insoluble, preservative-free pure powder. This agent was well mixed with 5% tragacanth gum solution at 20.0 mg/ml and diluted with normal saline to give a concentration of 2.0 mg/ml. The mice were given 2.5 mg/kg of RXM, one-half of the recommended human therapeutic dose, once a day for 4 weeks via a stomach tube. Clarithromycin (CAM) was also a gift from Abott Japan Co. Ltd. (Tokyo, Japan) as a preservative-free pure powder. CAM, dissolved in normal saline as in the case of RXM, was orally administered into mice at a dose of 7.0 mg/kg, one-half of the recommended human therapeutic dose, once a day for 4 weeks. josamycin (JM) was purchased from SIGMA Chemicals (St Louis, MO, USA) and dissolved in normal saline as was RXM. JM was also administered orally into mice at a dose of 20.0 mg/kg, the recommended human therapeutic dose, once a day for 4 weeks. AZM was extracted from ZITHROMAC dry syrup (Pfizer Co. Ltd., Tokyo, Japan) for pediatric use, which contains 100.0 mg of AZM, Yellow 5 and sodium lauryl sulfate. AZM was dissolved by suspending dry syrup in 5.0 ml of ethanol, and then homogenized with a sonic dismembrator for 5 min at 4°C, and centrifuged at 5000 rpm for 15 min at 4°C. The supernatants were collected and the ethanol was evaporated. The resultant powder was dissolved in saline as RXM administered orally into mice at a dose of 8 mg/kg once a day for 4 weeks. In all cases, the volume administered did not exceed 0.2 ml, and control mice received 5% tragacanth gum solution alone.

Lipopolysaccharide treatment
Mice were injected intraperitoneally with lipopolysaccharide (LPS) derived from Escherichia coli (SIGMA Chemicals) in a volume of 0.5 ml.

Preparation of plasma
Blood (1.0 ml) was obtained from cardiac puncture in the presence of 0.1 ml of heparin, and then centrifuged at 3000 rpm for 10 min at 4°C. Plasma was obtained and stored at −40°C until used.

Assay for NO (NO2/NO3)
To remove proteins from plasma, samples were filtered through centrifugal ultrafiltration devices at 5000 x g for 30 min at 4°C (Centricon YM-10; cut-off molecular weight, 10,000; Millipore Corp., Bedford, MA, USA). The NO levels in samples were examined by a NO assay kit that contained sufficient reagents (DojinDo, Co., Ltd, Kumamoto, Japan).

Assay for cytokines
Interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α) levels in plasma were examined using commercially available mouse cytokine enzyme-linked immunosorbent assay kits (R & D Corp., Minneapolis, MN, USA). The sensitivity of these kits for IL-1β, IL-6, and TNF-α was 3.0 pg/ml, 7.0 pg/ml, and 2.0 pg/ml, respectively.
Assay for inducible nitric oxide synthase mRNA expression

The lungs were obtained from mice after decapitation, and homogenized with a glass homogenizer at 4°C for 60 sec. Poly A⁺ mRNA was separated from homogenates with oligo(dT)-coated magnetic microbeads (Milteny Biotec, Bergische Gladbach, Germany). Inducible nitric oxide synthase (iNOS) mRNA was examined with mouse iNOS mRNA enzyme-linked immunosorbent assay test kits (R & D Corp.) according to the recommended manufacturer’s protocol.

Statistical analysis

Data were analyzed with analysis of variance followed by Fisher’s PLSD test. p < 0.05 was considered significant.

Results

Influence of macrolide antibiotics on NO production by LPS stimulation in vivo

The first experiments were undertaken to examine the time course of NO production after LPS injection. Plasma was obtained from mice 3, 5, 6, 7, and 8 h after injection of 5.0 mg/kg of LPS, and NO levels were examined. As shown in Fig. 1, intraperitoneal injection of LPS caused a transient increase in NO levels in plasma. NO levels in plasma gradually increased, peaked at 6–7 h, and decreased to control levels by 8 h after LPS injection.

The next experiments were carried out to examine the optimum concentration of LPS to induce NO production in mice. Donor mice were given intraperitoneal injections of 1.0, 2.5, 5.0, and 6.0 mg/kg of LPS, and plasma NO levels were examined 5 h later. The data in Fig. 2 shows that LPS injection of 1.0 mg/kg caused a significant increase in NO levels in plasma. NO levels in plasma were further increased when more than 5.0 mg/kg of LPS was used for stimulation of NO production.

We then examined the influence of macrolide antibiotics on NO production in response to LPS stimulation in vivo. To do this, mice were pre-treated with 2.5 mg/kg/day of RXM for 2–4 weeks. These mice received intraperitoneal injections of 5.0 mg/kg of LPS, and plasma NO levels were examined 5 h later. Although pre-treatment of mice with RXM for 2 weeks did not affect NO production in response to LPS stimulation in vivo, pre-treatment for longer periods (4 weeks) could suppress the ability of
mice to produce NO after LPS stimulation (Fig. 3). We further examined whether macrolide antibiotics except for RXM could also exert a suppressive effect on NO production induced by LPS stimulation. As shown in Fig. 4, AZM and CAM, but not JM, completely suppressed NO production induced by LPS stimulation.

FIG. 2. Dose-response profile of NO (NO$_2$/NO$_3$) generation by LPS injection in mice. ICR mice were injected intraperitoneally with various concentrations of LPS, and plasma was obtained 6 h later to assay NO$_2$/NO$_3$ levels. The data are expressed as the mean (μM) ± standard error of five mice. * Significant compared with normal control (0 μg/kg); ** significant compared with 2.5 mg/kg of LPS.

FIG. 3. Influence of RXM on NO (NO$_2$/NO$_3$) generation in response to LPS injection. ICR mice were administered orally with RXM once a day for 2 and 4 weeks at a dose of 2.5 mg/kg of RXM. The mice were then injected intraperitoneally with 5.0 mg/kg of LPS, and plasma NO$_2$/NO$_3$ levels were examined 6 h later. The data are expressed as the mean (μM) ± standard error of five mice. * Not significant compared with LPS alone; ** significant compared with LPS alone.
LPS stimulation. The data in Fig. 4 also show that the suppressive activity of AZM and CAM on NO production was much stronger than that of RXM.

**Influence of macrolide antibiotics on pro-inflammatory cytokine appearance in plasma after LPS injection**

The present experiments were performed to examine the influence of macrolide antibiotics on pro-inflammatory cytokine production by LPS injection. We first examined the time course of pro-inflammatory cytokine, IL-1β, IL-6 and TNF-α production after LPS injection. Normal mice were injected intraperitoneally with 5.0 mg/kg of LPS, and plasma samples were obtained 0 (before LPS injection), 1, 2, 3, and 4 h after LPS injection. As shown in Fig. 5 (upper panels), LPS injection caused a transient increase in pro-inflammatory cytokine levels in plasma; IL-1β and IL-6 levels in plasma peaked at 2 h, and then decreased to normal levels (before LPS injection) by 4 h. TNF-α levels in plasma also showed a similar pattern to those observed in IL-1β and IL-6, peaking 1 h after LPS injection and then decreasing to normal levels by 3 h. We next examined whether pre-treatment of mice with macrolide antibiotics could suppress pro-inflammatory cytokine production induced by LPS injection. Mice were pre-treated orally either with RXM, AZM, CAM or with JM once a day for 4 weeks. They were then injected intraperitoneally with 5.0 mg/kg of LPS, and plasma was obtained 1 h later for TNF-α assay, and 2 h later for IL-1β and IL-6 assays. As shown in Fig. 5 (lower panels), macrolide antibiotics without JM significantly suppress cytokine levels in plasma.

**Discussion**

Macrolide antibiotics are well known to be effective against Gram-positive bacteria and are frequently used in the treatment of upper and lower respiratory tract infections. Since the initial success of treatment of diffuse panbronchiolitis with erythromycin, the most famous 14-membered macrolide antibiotic, for longer than 3 months was reported by Kudoh et al., this therapy was used for the treatment and the management of airway inflammatory diseases, including chronic sinusitis with remarkable success. Much effort has been made to understand the mechanisms underlying the clinical efficacy of macrolides, and has revealed that the anti-inflammatory action of macrolides, but not bactericidal activity, is responsible for the effectiveness of macrolide therapy. However, the precise mechanisms are not well understood. The present results strongly suggest that the suppressive activity of macrolide antibiotics on NO generation in response to LPS stimulation in vivo may, in part, account for the clinical efficacy of macrolides on chronic inflammatory diseases. This conclusion may be supported by
the following observations: (1) long-term (4 weeks), but not short-term (2 weeks), administration of 14-membered macrolide antibiotics (RXM and CAM) could suppress NO generation in vivo; and (2)
treatment with the 16-membered macrolide antibiotic (JM), which is ineffective in clinical treatment, did not show any suppressive effects on NO generation. Recent reports clearly showed that long-term use of the 15-membered macrolide antibiotic (AZM) could improve lung function in patients with cystic fibrosis, which is a chronic inflammatory airway disease in Caucasians. These reports, and the present results showing the suppressive activity of AZM on NO generation, may also support the conclusion already described.

NO is generated in response to pro-inflammatory cytokine stimulations in a number of cell types (e.g. immune cells and fibroblasts), following induction of the inducible form of nitric oxide synthase, iNOS. Our previous work clearly showed that pre-treatment of mice with RXM decreases the ability of immune cells, such as T cells and macrophages, to produce pro-inflammatory cytokines induced by LPS injection, when the agent was administered into mice for longer than 4 weeks. From these reports, it is reasonable to speculate that pre-treatment of mice with macrolide antibiotics for 4 weeks decreases LPS-induced pro-inflammatory cytokine production and results in inhibition of NO generation. This speculation was supported by the present results showing that pro-inflammatory cytokine levels in plasma obtained from mice treated with macrolide antibiotics except for JM was lower than that from non-treated mice. iNOS, not present in quiescent cells, is often induced by inflammatory stimulations, and mediates the high levels of NO generation for long periods, resulting in tissue injury and mutations in cells. Recent reports have clearly shown that drugs, such as rebamipide and thiaton, inhibit the ability of iNOS to produce NO, and result in the prevention of intestinal damages caused by free radicals including NO. These reports leave open the question of whether the suppressive activity of macrolide antibiotics used in this study on NO production is due to its inhibitory action of iNOS generation by iNOS mRNA, or its suppression of iNOS activity to produce NO. We then examined iNOS mRNA expression in lung tissues. The present results clearly show that long-term administration of macrolide antibiotics could suppress iNOS mRNA expression, which is enhanced by LPS stimulation. Recently, much attention has focused on the toxicity of iNOS. Induction of excessive iNOS produces endothelial cell injury and inhibits cellular respiration, which can lead to cell dysfunction and cell death. It is also observed that iNOS could accelerate the production of a large amount of superoxide, which readily reacts with hydrogen to form the most toxic molecule, hydroxyl radical. The present results clearly show the inhibitory effects of macrolide antibiotics on iNOS mRNA expression, suggesting that these agents can cause a decrease in iNOS levels in cytosole and result in both suppression of superoxide generation and prevention of tissue injury in airway tracts. The conclusion restated is as follows. The suppressive effects of macrolide antibiotics, except for JM, on NO generation from fibroblasts may be one of the mechanisms leading to the favorable modification of airway inflammation in the macrolide therapy. This conclusion may be supported by clinical observations during the low-dose and long-term administration of macrolide antibiotics, showing the ineffectiveness of JM on airway inflammatory diseases.

References
1. Iino Y, Torigaya M, Kudo K, et al. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. *Avian Dis* 1992; 36(Suppl 157): 16–20.
2. Kozio N, Kudo S. Diffuse panbronchiolitis: role of macrodides in therapy. *Am J Respir Med* 2002; 1: 119–131.
3. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. *Lancet* 1996; 351: 420.
4. Aitchison EL. Azithromycin, the multifunction-resistent, and cyctic fibrosis. *Lancet* 1998; 351: 1286.
5. Suzuki H, Asano K, Ohki S, Kanai K, Mizutani T, Hisamitsu T. Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. *Med Inflamm* 1999; 8: 199–204.
6. Asano K, Kamakazu K, Hisamitsu T, Suzuki H. Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in vitro. *Int Immunopharmacol* 2001; 1: 1915–1921.
7. Ichikawa Y, Koga H, Tanaka M, et al. Neutrophilia in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. *Chest* 1990; 98: 917–923.
8. Shimane T, Asano K, Suzuki M, Hisamitsu T, Suzuki H. Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro. *Med Inflamm* 2001; 10: 232–332.
9. Murakata H, Suga M, Sato K, et al. Superoxide scavenging activity of erythromycin—iron complex. *Biochem Biophys Res Commun* 1997; 232: 183–187.
10. Kondo S, Adachi M, Asano K, et al. Influence of roxithromycin on cell-mediated immune responses. *Life Sci* 1992; 51: PL107–PL112.
11. Tayler BS, Geller DA. Regulation of the inducible nitric oxide synthase (iNOS) gene. In: Salvinem D, Billiar TR, Vodovota Y, eds. *Nitric Oxide and Inflammation*. Basel: Birkhauser Verlag, 2001: 191–202.
12. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev* 1991; 43: 109–142.
13. Lundberg JO, Farrants-Statlani T, Weitzberg E, et al. High nitric oxide production in human parasinal sinus. *Nat Med* 1995; 1: 370–373.
14. Zoritch B. Nitric oxide and asthma. *Arq Dis Child* 1995; 72: 259.
15. Kuro N, Royall JA, Ve YZ, Kelly DR, Beckman JS. Evidence for in vivo peroxinitrite production in human acute lung injury. *Am J Respir Crit Care Med* 1995; 151: 1250–1254.
16. Lanaro A, Jaliatti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. *J Pharmacol Exp Ther* 2000; 292: 156–163.
17. Asano K, Kamakazu K, Hisamitsu T, Suzuki H. Suppressive activity of macrolide antibiotics on nitric oxide production from nasal polyp fibroblasts in vitro. *Acta Otolarngol* 2003; 123: 1–6.
18. Kudo S, Uetake T, Hagiwara K, et al. Clinical effects of low-dose and long-term erythromycin chemotherapy on diffuse panbronchiolitis. *Nihon Kyobu Shikkan Gakkai Zasshi* 1987; 25: 63–69.
19. Cuzzocce R. Role of nitric oxide and reactive oxygen species in arthritis. In: Salvinem D, Billiar TR, Vodovota Y, eds. *Nitric Oxide and Inflammation*. Basel: Birkhauser Verlag, 2001: 145–160.
20. Ferdinandy P, Schulz P. Role of nitric oxide, superoxide, and peroxi- nitrite in myocardial ischemia-reperfusion injury and ischemic preconditioning. In: Salvinem D, Billiar TR, Vodovota Y, eds. *Nitric Oxide and Inflammation*. Basel: Birkhauser Verlag, 2001: 191–206.
21. Yermilow V, Rubio J, Ohshima H. Formation of 8-nitroguanin in DNA by human monocytes in vitro. *Ann N Y Acad Sci* 1992; 684: 109–125.
23. Kunitaka T, Miyazawa T, Kanatsu K, Kato S, Takeuchi K. Protective effect of thiaton, an antispasmodic drug, against indomethacin-induced intestinal damage in rats. *Jpn J Pharmacol* 2002; 88: 45–54.

24. Palmer RMJ, Bridge L, Foxwell NA, Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. *Br J Pharmacol* 1992; 105: 11–12.

25. Xia Y, Zweier JL. Superoxide anion release from inducible nitric oxide synthase. In: Salvemini D, Billiar TR, Vodovotz Y, eds. *Nitric Oxide and Inflammation*. Basel: Birkhauser Verlag, 2001: 27–39.

Received 23 April 2003
Accepted 12 May 2003